BWP
BMY.RT

Baldwin Wealth Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Baldwin Wealth Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-946
Closed -$1K – 644
2020
Q4 		$1K Hold
946
– – ﹤0.01% 548
2020
Q3 		$2K Buy
946
+175
+23% +$500 ﹤0.01% 514
2020
Q2 		$3K Hold
771
– – ﹤0.01% 503
2020
Q1 		$3K Hold
771
– – ﹤0.01% 509
2019
Q4 		$2K Buy
+771
New +$2K ﹤0.01% 527

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Baldwin Wealth Partners's BMY.RT Position: Q1 2021 in Review

Baldwin Wealth Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 946 shares — an estimated $1K sold.

Baldwin Wealth Partners first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $3K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Baldwin Wealth Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Baldwin Wealth Partners sold 946 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1K.
  • Baldwin Wealth Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Baldwin Wealth Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Baldwin Wealth Partners's 13F filing for Q1 2021, filed 8 Apr 2021.